Syneos Health

Syneos Health, Inc. engages in the provision of outsourced clinical development and commercialization services to biopharmaceutical companies. It operates through the following business segments: Clinical Solutions and Commercial Solutions. The Clinical Solutions segment offers clinical development services spanning Phase I to Phase IV, including global studies, as well as unbundled service offerings such as clinical monitoring, investigator recruitment, patient recruitment, data management, and study startup to assist customers with their drug development process. The Commercial Solutions segment provides commercialization services, including outsourced field selling solutions, medication adherence, communications, and consulting services. The company was founded in 1998 and is headquartered in Morrisville, NC.

Earnings data Q4 2019

Earnings data Q1 2020

Earnings data Q2 2020

Earnings data Q3 2020

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q1 2024

Syneos Health reports mixed Q4 results, focuses on growth strategies

Syneos Health's Q4 performance showed mixed results with revenue decline but growth on a constant currency basis. The company is focused on enhancing its operating model, customer engagement, and winning new business opportunities.
Challenges include evaluating spending by large pharma customers and the need for cost structure realignment. However, opportunities lie in engaging with analysts, driving cost savings, and expecting larger pharma awards in 2023.
Overall, Syneos Health remains confident in its strategy, investments, and ability to drive growth in Clinical. The company is navigating challenges while leveraging strengths in customer relationships and value-based pricing.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Syneos Health® (Nasdaq:SYNH) is the only fully integrated biopharmaceutical solutions organization. The Company, including a Contract Research Organization (CRO) and Contract Commercial Organization (CCO), is purpose-built to accelerate customer performance to address modern market realities. We bring together approximately 24,000 clinical and commercial minds with the ability to support customers in more than 110 countries. Together we share insights, use the latest technologies and apply advanced business practices to speed our customers’ delivery of important therapies to patients.

Syneos Health's (SYNH) first-quarter 2023 earnings and revenues beat estimates. The company enters into a definitive merger agreement to be acquired by a private investment consortium.

Syneos Health (SYNH) Tops Q1 Earnings, Announces Merger Plan

NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Syneos Health, Inc. (NasdaqGS: SYNH) to a consortium of affiliates of Elliott Investment Management, Patient Square Capital, and Veritas Capital. Under the terms of the proposed transaction, shareholders of Syneos will receive only $43.00 in cash for each share of Syneos that they own. KSF is seeking to determ.

SYNEOS HEALTH INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Syneos Health, Inc. - SYNH

NEW YORK , May 10, 2023 /PRNewswire/ -- Rowley Law PLLC is investigating potential securities law violations by Syneos Health, Inc. (NASDAQ: SYNH) and its board of directors concerning the proposed acquisition of the company by a consortium of private investment firms. Stockholders will receive $43.00 for each share of Syneos Health stock that they hold.

ALERT: Rowley Law PLLC is Investigating Proposed Acquisition of Syneos Health, Inc.

MILWAUKEE , May 10, 2023 /PRNewswire/ -- Ademi LLP is investigating Syneos Health (Nasdaq: SYNH) for possible breaches of fiduciary duty and other violations of law in its transaction with the Investment Consortium.  Click here to learn how to join the action https://www.ademilaw.com/case/syneos-health-inc or call Guri Ademi toll-free at 866-264-3995.

Shareholder Alert: Ademi LLP investigates whether Syneos Health, Inc. has obtained a Fair Price in its transaction with the Investment Consortium

Syneos Health (SYNH) came out with quarterly earnings of $0.75 per share, beating the Zacks Consensus Estimate of $0.67 per share. This compares to earnings of $1.01 per share a year ago.

Syneos Health (SYNH) Q1 Earnings and Revenues Surpass Estimates

Syneos Health (NASDAQ: SYNH ) stock is on the rise Wednesday as investors react to news of a $7.1 billion acquisition deal. A group of investors led by Elliott Investment Management intend to take the healthcare company private for a price of $43 per share.

SYNH Stock Alert: The $7 Billion Reason Syneos Health Is Up Today

NEW YORK--(BUSINESS WIRE)--Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Syneos Health, Inc. (NASDAQ: SYNH) to a consortium of affiliates of Elliott Investment Management, Patient Square Capital, and Veritas Capital for $43.00 per share in cash is fair to Syneos shareholders. Halper Sadeh encourages Syneos shareholders to click here to learn more about their legal rights and options or contact Daniel Sadeh or Zachary Halper at (212) 763-0060 or sadeh@halper.

SYNH STOCK ALERT: Halper Sadeh LLC Is Investigating Whether the Sale of Syneos Health, Inc. Is Fair to Shareholders

The sale of Syneos Health comes as the company faces muted spending from drug developers for its clinical-research services.

Syneos Health Stock Rises on $7.1 Billion Sale to Private Group

MORRISVILLE, N.C., May 10, 2023 (GLOBE NEWSWIRE) -- Syneos Health (Nasdaq:SYNH), a leading fully integrated biopharmaceutical solutions organization, today reported financial results for the three months ended March 31, 2023.

Syneos Health Reports First Quarter 2023 Results

Syneos Health Inc.'s stock SYNH soared 9% in premarket trade Wednesday, after the biopharma services company said it has agreed to be acquired by a private investment consortium for about $7.1 billion in cash. Under the terms of the deal, the consortium of Elliott Investment Management, Patient Square Capital and Veritas Capital will pay $43 per Syneos Health stock, equal to a 24% premium over the stock's closing price on Feb. 13, the last trading day prior to media reports of a possible deal.

Syneos Health to be acquired by private investment consortium for about $7.1 billion in cash

Shareholders to Receive $43.00 Per Share in Cash Represents 24% Premium to Unaffected Stock Price MORRISVILLE, N.C., May 10, 2023 (GLOBE NEWSWIRE) -- Syneos Health, Inc. (Nasdaq: SYNH) (“Syneos Health” or the “Company”), a leading fully integrated biopharmaceutical solutions organization, today announced that it has entered into a definitive agreement to be acquired by a consortium of private investment firm affiliates composed of Elliott Investment Management (“Elliott”), Patient Square Capital (“Patient Square”), and Veritas Capital (“Veritas”) for $43.00 per share in cash in a transaction valued at approximately $7.1 billion, including outstanding debt.

Syneos Health to be Acquired by a Private Investment Consortium for Approximately $7.1 Billion

Syneos Health Inc.'s SYNH stock surged 19% in extended trading Tuesday on a Bloomberg report that a consortium of Elliott Investment Management, Patient Square Capital and Veritas Capital is in advanced talks to acquire Syneos, a drug-research services company. A deal could be announced as soon as this week, according to people with knowledge of the talks, the report said.

Syneos Health's stock soars 19% on acquisition report

Syneos Health's (SYNH) share price movement is expected to be favorable due to the strength of the company's Syneos One portfolio and several value-added partnership deals.

Here's Why Investors Should Retain Syneos Health (SYNH) for Now

Finance Leader with 30+ Years of Experience, Including 15 Years in Clinical Research Industry Finance Leader with 30+ Years of Experience, Including 15 Years in Clinical Research Industry

Syneos Health Appoints Michael Bonello as Chief Financial Officer

Coinbase

First Republic

JPMorgan Chase & Co

Microsoft

Charles Schwab

SVB Financial Group

UBS Group AG

CashFlow Hunter returns to discuss launching his new Investing Group, Catalyst Hedge Investing. Coinbase not evolving from early mover status in crypto; Bitcoin a solution looking for a problem.

CashFlow Hunter On Catalyst Hedge Investing, Coinbase, 3M, Schwab And UBS

MORRISVILLE, N.C., April 13, 2023 (GLOBE NEWSWIRE) -- Syneos Health® (Nasdaq:SYNH), a leading fully integrated biopharmaceutical solutions organization, will release its first quarter 2023 financial results on Wednesday, May 10th, 2023, prior to its earnings call at 8:00 a.m. ET.

Syneos Health Schedules First Quarter 2023 Earnings Call for Wednesday, May 10th, 2023

Dealreporter article says that multiple PE firms are bidding for the company and even named advisors the company has hired. Private equity math works given relatively low current leverage and high cash generation.

Syneos Health: Rumors Of Private Equity Circling, Potential 40% Upside

Company Recognized for Positive Vaccine Expertise Contributions Company Recognized for Positive Vaccine Expertise Contributions

Syneos Health Wins 2023 ViE Award

MORRISVILLE, N.C., April 04, 2023 (GLOBE NEWSWIRE) -- Syneos Health® (Nasdaq: SYNH), a leading fully integrated biopharmaceutical solutions organization, today announced Jeanine O'Kane as President of Syneos Health Communications — a portfolio of agencies spanning advertising, public relations, patient advocacy, medical communications, managed markets, and naming and branding. Formally President of the US Public Relations Group at Syneos Health Communications, Jeanine has been with the organization for more than a decade and has more than 20 years of industry experience.

Syneos Health Names Jeanine O'Kane as Communications President

Program Drives Digital and Omnichannel Engagement for Medical Science Liaison Teams & Medical Conferences Program Drives Digital and Omnichannel Engagement for Medical Science Liaison Teams & Medical Conferences

Syneos Health Launches Medical Affairs Digital Amplifier

Medtronic

Henry Schein

Stryker

MedTech player like Medtronic (MDT) are integrating artificial intelligence (AI) capabilities to aid therapeutic and diagnostic applications.

MedTech Bigwigs in Spotlight as AI Revolutionizes Healthcare

Syneos Health's (SYNH) partnership with KX is likely to accelerate clinical trial execution using AI-enabled solutions.

Syneos Health (SYNH) Partners With KX for Data-Driven Insights

Collaboration Will Leverage Data Analytics and AI to Accelerate Clinical Trial Execution Collaboration Will Leverage Data Analytics and AI to Accelerate Clinical Trial Execution

Syneos Health and KX Partner to Pioneer Data-Driven Transformation in Biopharmaceutical Asset Development

With the multi-year deal, Syneos Health (SYNH) aims to deliver technology and data solutions with Microsoft.

Syneos Health's (SYNH) New Microsoft Deal to Expand AI Usage

Collaboration Leverages AI-ready Technology to Speed Asset Development and Optimize Performance Collaboration Leverages AI-ready Technology to Speed Asset Development and Optimize Performance

News for Syneos Health Stock (SYNH)